Fibrobiologics, INC 8-K filings

FibroBiologics, Inc. received a Staff Determination from Nasdaq indicating intent to delist its securities due to failing to meet the minimum $1.00 bid price requirement for over 30 consecutive business days.

FibroBiologics, Inc. announced the appointment of Kathleen Rubins, Ph.D., a former NASA astronaut and microbiologist, to its Board of Directors, effective July 8, 2026.

FibroBiologics, Inc. announced the closing of a private placement raising $3 million, with potential for an additional $6 million upon warrant exercise, to fund working capital and general corporate purposes.

FibroBiologics, Inc. has updated its At The Market (ATM) offering, increasing the potential aggregate offering price to $7.5 million.

FibroBiologics, Inc. announced the grant of stock options to its CEO, CFO, CSO, and General Counsel, with specific vesting schedules tied to continued service.

FibroBiologics, Inc. has entered into an At-The-Market (ATM) offering agreement with H.C. Wainwright & Co. to sell up to $6.15 million of its common stock.

FibroBiologics has successfully resolved its Nasdaq listing compliance issues regarding stockholders' equity and bid price requirements.

FibroBiologics, Inc. has amended its bylaws to reduce the stockholder meeting quorum requirement from a majority to one-third of voting power.

FibroBiologics amends prior filing to include lease termination, saving approximately $0.8 million in future rent payments.

FibroBiologics, Inc. has terminated its sublease agreement early, resulting in significant cost savings and a consolidation of operations.

FibroBiologics, Inc. has officially executed a 1-for-20 reverse stock split, effective March 30, 2026, to adjust its issued and outstanding common stock.

FibroBiologics, Inc. has closed a $3 million public offering of common stock and warrants to support working capital and general corporate purposes.

FibroBiologics, Inc. announced that its Compensation Committee approved a new annual base salary of $400,000 for CFO Jason D. Davis, effective January 1, 2026.

FibroBiologics, Inc. stockholders approved a reverse stock split and the issuance of shares related to outstanding warrants at a Special Meeting held on February 20, 2026.

FibroBiologics, Inc. received a formal notice from Nasdaq regarding continued non-compliance with listing rules, posing a delisting risk.

FibroBiologics, Inc. received a second delisting notice from Nasdaq for failing to meet the minimum bid price requirement, prompting plans for an appeal and a reverse stock split proposal.

FibroBiologics, a clinical-stage biotech, announced a registered direct offering and concurrent private placement to raise approximately $1.7 million for working capital and general corporate purposes.

FibroBiologics, a clinical-stage biotechnology company, announced a registered direct offering and concurrent private placement to raise approximately $1.5 million for working capital and general corporate purposes.

FibroBiologics, a clinical-stage biotechnology company, announced a $4 million registered direct offering and concurrent private placement, funded by sovereign-issued gold coins, to strengthen its capital structure and satisfy debt.

FibroBiologics, Inc. received a Nasdaq notification for failing to meet the minimum $35 million Market Value of Listed Securities requirement.

FibroBiologics, Inc. filed an amendment to its Form 8-K, clarifying the maximum number of shares that may be issued under its $15 million Standby Equity Purchase Agreement with YA II PN, Ltd.

FibroBiologics, Inc. disclosed recent conversions of convertible promissory notes by YA II PN, Ltd., resulting in the issuance of over 2.1 million common shares and significant remaining note balances.

FibroBiologics, Inc. has received a notification from Nasdaq regarding its non-compliance with the minimum bid price requirement, initiating a 180-day period to regain compliance.

FibroBiologics, a clinical-stage biotechnology company, announced the closing of the third $5 million tranche of its $15 million pre-paid advance from YA II PN, Ltd., completing the initial funding under a larger $25 million Standby Equity Purchase Agreement.

FibroBiologics, Inc. announced the results of its Annual Meeting of Stockholders, including the election of two Class II directors and the approval to significantly increase its authorized capital stock.

FibroBiologics, a clinical-stage biotechnology company, has appointed Jason D. Davis, a CPA with over two decades of public company and capital markets experience, as its new Chief Financial Officer, effective immediately.

FibroBiologics, Inc. announces the voluntary resignation of Interim CFO Robert E. Hoffman, effective May 14, 2025, as he pursues another opportunity, though he will remain on the Board of Directors.

FibroBiologics satisfied a commitment fee by issuing shares and further shares were issued upon conversion of a convertible promissory note.

FibroBiologics, Inc. discloses the approved fiscal 2024 annual incentive bonuses for its Named Executive Officers and Interim Chief Financial Officer.

FibroBiologics has received the second $5 million tranche of a $25 million financing agreement with YA II PN, LTD.